{
  "context": {
    "rules": [
      "Rule1: Patient response is positive or side effects are minimal.",
      "Rule2: Whenever side effects are minimal, the medication is safe.",
      "Rule3: If regulatory standards are compliant, then the manufacturing process is approved.",
      "Rule4: Regulatory standards are compliant or equipment is validated.",
      "Rule5: Assuming equipment is validated, then if it is not the case that positive patient response leads to a successful clinical trial, the trial period is not extended.",
      "Rule6: In the event that phase three is initiated, the clinical trial is approved.",
      "Rule7: Given that contamination is detected, the batch is not contaminated.",
      "Rule8: Should an impurity be identified, the batch is not contaminated.",
      "Rule9: If recall procedure is initiated, then quality assurance is failed.",
      "Rule10: Provided that the product line is profitable, market share is increased.",
      "Rule11: The product line is profitable or positive patient response implies a successful clinical trial.",
      "Rule12: In the case that production is resumed, production is not halted.",
      "Rule13: If the drug formula is effective, then the medication is safe.",
      "Rule14: Either the drug formula is effective or the chemical compound is stable.",
      "Rule15: The batch is contaminated or if the chemical compound is stable, then the medication is safe.",
      "Rule16: Should the quality test be passed, the batch is not contaminated.",
      "Rule17: Either the quality test is passed or sterilization is approved.",
      "Rule18: Provided that sterilization is approved, packaging is completed.",
      "Rule19: In the event that packaging is completed, the batch is not contaminated.",
      "Rule20: If it is not the case that positive patient response implies a successful clinical trial, then the trial period is extended.",
      "Rule21: If it is not the case that conducted microbial testing leads to either detected contamination or identified impurity, then recall procedure is initiated.",
      "Rule22: Provided that it is not the case that not not safe medication implies initiated phase three leads to completed phase three, then the FDA application is submitted.",
      "Rule23: In the case that it is not the case that not not safe medication implies initiated phase three leads to completed phase three, then the FDA application is not submitted.",
      "Rule24: If it is not the case that not safe medication implies approved clinical trial, then production is halted.",
      "Rule25: Assuming it is not the case that not safe medication implies approved clinical trial, production is resumed.",
      "Rule26: Whenever the medication is not safe, the clinical trial is not approved."
    ],
    "facts": [
      "Fact1: Microbial testing is conducted.",
      "Fact2: It is not the case that the clinical trial is successful.",
      "Fact3: The manufacturing process is not approved.",
      "Fact4: Phase three is not completed.",
      "Fact5: Quality assurance is not failed.",
      "Fact6: Market share is not increased."
    ]
  },
  "question": "The medication is safe."
}